Severe Acute Respiratory Syndrome (SARS) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Severe Acute Respiratory Syndrome (SARS) – Drugs In Development, 2024 report and make more profitable business decisions.
Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea, and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS.
The Severe Acute Respiratory Syndrome (SARS) drugs in development market research report provide comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Severe Acute Respiratory Syndrome (SARS) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 48 molecules, with 43 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Severe Acute Respiratory Syndrome (SARS) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Severe Acute Respiratory Syndrome (SARS) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Severe Acute Respiratory Syndrome (SARS) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aligos Therapeutics IncAmide Technologies Inc
Autoimmune Technologies LLC
Beroni Group Ltd
Biotron Ltd
BioVaxys Technology Corp
Calder Biosciences Inc
Chemomab Therapeutics Ltd
Cidara Therapeutics Inc
Citospin SL
Cloud Pharmaceuticals Inc
Cocrystal Pharma Inc
ConserV Bioscience Ltd
CoV Biotechnology Pte Ltd
Dominari Holdings Inc
FUDAN University
Global BioLife Inc Ltd
Halo Therapeutics Ltd
Hinge Bio Inc
Immodulon Therapeutics Ltd
Immune Biosolutions Inc
Infex Therapeutics Ltd
Invivyd Inc
Merck KGaA
Novavax Inc
Oncolys BioPharma Inc
Phelix Therapeutics LLC
Pulmotect Inc
ReVacc Biotech
Sagimet Biosciences Inc
Sorrento Therapeutics Inc
Theravectys SA
Thylacine Biotherapeutics Inc
Trimunocor Ltd
University of Missouri
University of North Carolina at Chapel Hill
University of Queensland
Valo Therapeutics Oy
Vanderbilt University
VBI Vaccines Inc
Westlake Pharma Inc
Wuhan Healthgen Biotechnology Corp
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Severe Acute Respiratory Syndrome (SARS) reports